UCL WIKI

UCL Logo
Skip to end of metadata
Go to start of metadata

Click on the paperclip at the top of the page to add, remove or edit files. If possible, please add a row to the table below to allow easy access to your slides.


9 May 2012

PUW1

Joanna

Immunology

16 May 2012

WCJ

Angelina

Zidovudine PK/PG

23 May 2012

PUW2

Jig

LMWH in pregnancy

30 May 2012

No meeting



6 June 2012

PUW1

Joe

Antimicrobial PKPD

13 June 2012

PUW1

Terry Shepard

Geriatric PKPD

20 June 2012

PUW2

Rollo/Joanna

Immunology modelling

27 June 2012

No meeting



4th July 2012

No meeting



11th July 2012

PUW2

Julie

PAGE review

18th July 2012

PUW2

Katie

Gentamicin in burns

12/10/12 1pm

WCA

Rollo

Modelling of the immune reconstitution post BMT

19/10/12 1pm

PUW3

Joe

Prague Biometrics 2012;68:902-11

26/10/12 1pm

PUW3

Charlotte

NAPPA (Beta lactam pharmacokinetics/pharmacodynamics) plans

2/11/12 1pm

PUW3

Eva

Neogent (developing Bayesian therapeutic drug monitoring) progress

9/11/12 1pm

PUW3

Joanna

Inference methods course review

16/11/12 1pm

PUW2


General discussion

23/11/12 1pm

PUW3

Julie

Covariate selection methods in pharmacokinetic modelling

30/11/12 1pm

PUW3

Julie

NCA versus modelling in phase I studies for drugs with long half-life

7/12/12 1pm

PUW3


Goldacre talk

14/12/12 1pm

PUW3

Lilia

Neutropenia post-BMT

4/1/13 1pm

PUW3


General discussion

11/1/13 1pm

Levinsky

Joe

Maraviroc PK

18/1/13 1pm

PUW4

Andrezj

PKPD bridging of response between adults and children

25/1/13 1pm

PUW3

Lilia

Neutropenia following paediatric BMT

1/2/13 1pm

PUW1

Mirjam Trame

Use of PKPD modeling to guide HIV understanding and treatment

8/2/13 1pm

PUW3

Sami

Bioequivalence studies and genetic variability

15/2/13 1pm

PUW1

Liana

ErbB inhibition for PKD

22/2/13 1pm

PUW3

Alienor Berges (GSK)


1/3/13 1pm

PUW4

Rollo

CD4 reconstitution post BMT 

8/3/13 1pm

PUW3

Eva

Neogent update

15/3/13 1pm

PUW4

Tafi

Dose individualisation in HIV/AIDS and TB patients on Efavirenz (EFV).

22/3/13 1pm

PUW3

Hui Ma

Genetic components to glucose-insulin response

26/4/13 1pm

PUW3

Sarit

FA and bioavailability

10/5/13 1pm

PUW3

Tafi

Common adverse drug reactions linked to HIV and/or TB medication: Lipodystrophy, Skin Hypersensitivity, CNS and Peripheral Neuropathy.
(To appear in the Journal of AIDS and Clinical Research, 2013).

28/5/13 1pm

PUW1

Charlotte

Use of meta-analysis in evidence synthesis: an example  based on dose selection for antibiotics (PAGE talk)

31/5/13 1pm

PUW1

Rollo

Modelling immune reconstitution in children post HSCT (PAGE talk)

7/6/13 1pm

PUW3

Julie

Penalized regression implementation within the SAEM algorithm to advance high-throughput personalized drug therapy (PAGE talk)

21/6/13 1pm

PUW1

Bruce Green

Therapeutic Drug Monitoring

16/9/13 1pm

PUW3

Joe

Diagnostics for bivariate regression models

23/9/13 1pm

PUW3

No meeting

Julie Seminar on Tues 24/9.

30/9/13 1pm

PUW2

Jan-Stefan Van der Walt

Nonlinear mixed effects model for saliva cortisol and cortisone in patients with Addisons disease and healthy volunteers.

1/10/13 1pm EXTRA MEETING

PUW4

Stefanie Hennig

Changes in between subject variability with covariate models in pharmacometrics

7/10/13 1pm

PUW2



14/10/13 1pm

PUW3

Tafi

TBA

21/10/13 1pm

PUW2

Julie

Modelling of tenofovir and emtricitabine PK in the ANRS 134-COPHAR 3 trial (work in progress)

28/10/13 1pm

PUW3

Joanna

CD4 recovery in the CHER study

4/11/13 1pm

PUW2

Eva

Upgrade talk practice

11/11/13 1pm

PUW3

Flora Musuamba

Use of modelling and simulation tools to improve decision-making in drug development and clinical practice

18/11/13 1pm

PUW2

Joe

Decision theory and antimicrobials

25/11/13 1pm

PUW3

Andreas

Pain PKPD

2/12/13 1pm

TWC F

No meeting


9/12/13 1pm

PUW3

Pieter de Cock

Paediatric antimicrobial PKPD in ICU

16/12/13 1pm

PUW3

Rollo

Modelling TCR repertoire (not with NLME!)

20/1/14

PUW3

Jessica Soto

Modelling taste studies

27/1/14

PUW1

Joanna

Practice for South Africa

3/2/14

PUW3

Liana

PK of tyrosine kinase inhibitors in PKD animal model

10/2/14

PUW4

Eva

Neogent predictions

17/2/14

PUW3

Deji

Hepatitis and HIV co-infection modelling

24/2/14

PUW1



3/3/14

PUW2

Rollo

Upgrade practice

10/3/14

PUW1

Joe

Clonidine PKPD for sedation in PICU

17/3/14

PUW3

Andreas

Clinical protocol development for GAbapentine in Paediatric pain Project : Optimization of the trial design characteristics based on (E)D optimality using popED.

24/3/14

PUW3

Julie

MRC Biostats talk on new methods for genetic covariates in PKPD modelling.

31/3/14

PUW1

Flora

Clinical protocol development for GAbapentine in Paediatric Pain Project : Dose rationale and dosing schedule for characterisation efficacy in chronic pain

7/4/14

PUW3

Morris

Development and dose rationale for fixed dose combinations for the treatment of tuberculosis

14/4/14

WCD

Andrezj

Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality

26/4/14

PUW4



12/5/14

PUW2

Carlos Hoyo

Nifedipine PKPD

19/5/14

WCC

Gavin Jarvis

A Modelling Approach to the Genetics of Embryonic Growth

23/6/14

PUW3

All

PAGE meeting review

30/6/14

PUW2

Flora

NLME cluster demonstration

7/7/14

PUW1

Sophie Rhodes

The immune response to BCG vaccination over time and the population variation of immune response dynamics

14/7/14

PUW2

Joanna and Jamie

An ODE model of peptide presentation by MHC-I / Geometric MCMC




SUMMER

1/9/14

LGSR

Joe

Antimicrobial PKPD   IDM_clinpharm_Standing_2014.pdf

8/9/14 meeting starts 2pm

Levinski

Julie

DDMore language

15/9/14

LGSR

Paul

Pharmacogenetics of diclofenac

22/9/14

LGSR

Yucheng

Count data models and introduction to Pirana

29/9/14

LGSR

Andreas

Gabapentin PKPD in paediatric neuropathic pain

6/10/14

LGSR

Liana

Tyrosine kinase inhibitor effects in polycystic kindney disease

13/10/14

LGSR

Joanna


20/10/14

LGSR

Rollo

Short-term neutrophil and lymphocyte HSCT models

27/10/14

LGSR

Eva

NeoGent PKUK practice

3/11/14

LGSR

Seb

Item Response Theory: Application to NLME

10/11/14

LGSR

Joe

A new mechanistic model for antiretroviral pharmacodynamics 

17/11/14

LGSR

Alberto

Anaesthesia depth with 3 different EEG measures

24/11/14

LGSR

Suzanne Reeves

Mechanisms underpinning antipsychotic sensitivity in Alzheimer's disease

1/12/14

LGSR

Deji

Mixed Effect Modelling in Hep C-HIV coinfected children

8/12/14 meeting starts at 2pm

LGSR

TBC

To be confirmed

15/12/14

LGSR

Morris

Understanding the determinants of drug exposure and pharmacokinetic variability in tuberculosis patients

Date

Location*

Presenter

Topic

12/1/15PUW3Lynette PheeModelling antimicrobial synergy
19/1/15PUW3Michael BetancourtBayesian approaches in NLMEM
26/1/15PUW4Dejipre-Upgrade Talk
2/2/15PUW3JoeStudy design peer review/journal club
9/2/15PUW3EvaComparing methods for paediatric PK scaling
16/2/15PUW3Ajay SinhaAmikacin and Vancomycin PK in neonates
23/2/15PUW4Julie

Joint modeling of Tenofovir plasmatic and intracellular concentrations - The COPHAR3 trial

2/3/15PUW3Karin SeifertEstablishing PK/PD relationships of anti-leishmanial drugs
9/3/15PUW3JoeAntimicrobial PKPD, refresher and future directions
16/3/15PUW3SophieVaccine dyamics with NLME
23/3/15PUW4SuzanneAmisulpride PKPD
30/3/15PUW3MorrisDeterminants of variability in drug exposure and implications for dose selection in tuberculosis patients
13/4/15PUW2AndreasGabapentin for neuropathic pain
20/4/15PUW3JoeNLME tutorial
27/4/15PUW4YuchengPropofol in ICU
11/5/15PUW3IblalBenzylpenicillin neonatal PK
18/5/15PUW3JoePK of combination therapy in resistant Gm -ves
1/6/15PUW3

8/6/15PUW3LianaPKPD of in vivo PKD model
15/6/15PUW3AllPAGE review
22/6/15PUW3EvaPD neonatal infection modelling
29/6/15PUW4SuzannePKPD of amisulpride
6/7/15PUW3LudoPKPD in veterinary medicine
13/7/15PUW3Roger GunnPK-PD modelling of CNS PET Molecular Imaging Studies
7/9/15PUW3AiweiDexmeditomidine PKPD
14/9/15PUW3EvaMeropenem in late onset sepsis and meningitis in neonates
21/9/15PUW3LudoDexmeditomidine PKPD (in veterinary subjects)
28/9/15PUW3BenModelling HCMV
5/10/15PUW1SuzanneAmisulpride PK update
12/10/15PUW1David MoorePKPD in TB
19/10/15PUW1JoePersonalised medicine with PKPD
26/10/15PUW1Imperial GroupAntimicrobial decision support
2/11/15PUW1

9/11/15PUW2RolloPhD viva prep talk
16/11/15PUW2EvaIRT for neonatal sepsis
23/11/15PUW2FrankPKPD in malaria
30/11/15PUW2Morris

PBPK Modelling in TB

7/12/15PUW2LianaPKD PKPD
14/12/15PUW2Pratima ChowdaryIndividualised dosing in haemophilia

Date


Location*

Presenter

Topic

1/2/16PUW3DejiHIV models in children
4/4/16PUW2MorrisModel-based translational research in tuberculosis

4/7/16

PUW2

AlbertSiRNA PD in neuroblastoma
6/2/16PUW1CharlotteUpdate on NAPPA

6/6/16

PUW2

No meetingPAGE
7/3/16PUW3FrankIn vitro TB PD

9/5/16

PUW3

Joy DawesMorphine and dexmeditomidine PK in children
11/4/16PUW3Oliver StirrupAdult NLME in HIV under HAART

11/7/16

PUW2

No MeetingTo be rescheduled: Min - NAPPA amoxicillin/co-amoxiclav PK results

13/6/16

PUW2

GeorgieFlucloxacillin PK: Neonatal results from NAPPA
14/3/16PUW3JulieBayesian inference in high-throughput pharmacogenetics
15/2/16PUW3YuchengCount data modelling of BATA

16/5/16

PUW3

JulieJoint modelling of plasmatic and intracellular concentrations of Tenofovir (TDF) and Emtricitabine (FTC) - The COPHAR3 trial
18/1/16PUW3Planning meeting
18/4/16PUW3BenIncorporating immunity into CMV models

20/6/16

PUW2

Dan Wright

Model-based dose prediction: the curious case of allopurinol

21/3/16PUW2DejiModelling poor immune response in HIV-infected children
22/2/16PUW3BenCMV model update

23/5/16

PUW2

LetiziaPBPK in TB
25/1/16Levinski roomJoeScaling in PK and PD
25/4/16PUW3Per Olsson

Life as a pharmacometrics consultant

27/6/16

PUW2

Salvo

Neonatal antimicrobial PK

29/2/16PUW2FabriziaPKPD in neurology

Date


Location*

Presenter

Topic

12/9/16PUW4Joanna LewisCHER, chlamydia and reproducibility: a view from Imperial
19/9/16PUW4All
R-script repository
26/9/16PUW4BenCMV PKPD update
3/10/16PUW1Lucy HutcinsonPreclinical PD modelling in oncology
10/10/16PUW1Matt JayBayesian analysis of morphine safety in children
17/10/16PUW1Huixin Yu
PK/PD modelling & simulation for anticancer drugs with complex absorption characteristics
24/10/16PUW1MorrisModelling combination therapy in tuberculosis
31/10/16PUW1Dagan LonsdaleUpdate on ABDose
7/11/16LevinskyAiwei LiDexmeditomidine PKPD
14/11/16LevinskyAmy Cheung/James YatesQSP in paediatrics/Of mice and more
21/11/16LevinskyGraceNeonatal and paediatric antimicrobials
28/11/16Levinsky

5/12/16Levinsky

12/12/16PUW1Chris WPBPK modelling of dexamethasone + selumetinib in combination in adults and children
19/12/16PUW1CharlotteUpdate on NAPPA

Date

Location*

Presenter

Topic

19/12/16 (12:00)PUW1CharlotteUpdate on NAPPA
16/1/17 PUW4FrankPractice MRC interview
23/1/17PUW4JoeFLACSAM PK results
30/1/17PUW4AllPaediatric sample size discussion
6/2/17PUW4FrankUpdate on treosulfan/TB work
13/2/17PUW4Mike and SophidaMRes project outline
20/2/17PUW2BenCMV PD
27/2/17PUW2CharlotteNAPPA update
6/3/17PUW2MorrisRationale for dose selection in tuberculosis: how to scale from mouse to human?
13/3/17PUW2Benjamin Blaise
iSleep/iCare - real-time metabolic support for personalized intensive care
20/3/17PUW2

27/3/17PUW2Aubrey CunninghamAdjunctive therapy for severe malaria
3/4/17PUW2BelenPhD update
10/4/17PUW2

24/4/17PUW1Annegret Dahlmann-noorPKPD in ophthalmology
8/5/17PUW1Paul BaverelTralokinumab, an investigational anti-IL13 monoclonal antibody: PK & exposure-response modeling to bridge adult and paediatrics clinical development plan
15/5/17PUW1MorrisTB modelling PAGE practice
22/5/17PUW1BenCMV modelling ESPID practice
5/6/17PUW1
No meeting
12/6/17 (12:00)PUW3AllPAGE review
19/6/17PUW1LudoHFIM progress
26/6/17PUW1Maria ScarpaEnd-user acceptability of orodispersible films (ODF) for delivery of medicine
3/7/17PUW1

10/7/17PUW1

17/7/17PUW1

30/10/17Levinsky

27/11/17LevinskyWatyCovariate analysis with supervised machine learning
25/9/17PUW2YomnaTreosulfan PK
23/10/17Levinsky

20/11/17Levinsky
Nicolas Fanget
Publishing in Nature journals
18/12/17LevinskyLudoHFIM modelling progress
18/9/17LevinskySophidaPosaconazole pharmacokinetics in children
16/10/17LevinskyMandy WVitamin D PKPD plans
13/11/17LevinskyShan PanApplication of pharmacometrics in rheumatoid arthritis: case studies in clinical practice and drug development
11/12/17LevinskyVickyRivaroxaban PKPD
11/9/17Levinsky
no meeting
9/10/17Levinsky

6/11/17LevinskyJuliePK of serum and intra cellular sustained-release Lithium
4/12/17LevinskyJuliePK of total, unbound and intra cellular MPA
2/10/17LevinskyOfranGender differences in infant mortality in UK PICUs
8/1/18PUW 4planning meeting
15/1/18PUW 4
Haifa
Posaconazole study protocol
22/1/18PUW 4FrankVancomycin PKPD
29/1/18PUW 4DaganResults from ABDose
5/2/18PUW 4ShanSalbutamol PKPD
12/2/18PUW 4DionnaCoMPLEX mini project
19/2/18PUW 3

26/2/18PUW 3BernTB-PRACTECAL trial PK-PD study design
5/3/18Levinski 12:00 startAyeshaRituximab PKPD
12/3/18PUW 3BenStatistical Challenges in T Cell Receptor Repertoire Immunophenotyping
19/3/18PUW 3JoePosaconazole PK
26/3/18PUW 1WatyMachine learning approaches
9/4/18PUW 3

16/4/18PUW 3planning meeting
23/4/18PUW 3no meeting ECCMID
30/4/18PUW 3JigAnticoagulant PKPD in haemodialysis
14/5/18PUW 3FrankModelling progress in TB
21/5/18PUW 3no meeting PK course
4/6/18PUW 3MaddliePhD introduction: PKPD modelling of sedative and analgesic effects
11/6/18PUW 3Komal BhatiaInfant growth in urban informal settlements (slums) in Mumbai, India
18/6/18PUW 3ShanPsoriasis PKPD modelling
25/6/18PUW 3Oleg VolkovOptimal design in PKPD
2/7/18PUW 3BenCMV modelling
9/7/18PUW 3JulieModel-based bioequivalence




3/9/18PUW 3planning meeting
10/9/18PUW3FrankModelling of in vitro antimicrobial experiments
17/9/18PUW3no meeting
24/9/18PUW3SatveerNIHR practice psoriasis TDM
1/10/18PUW1OfranNIHR practice
8/10/18PUW1JulieDynamic individual predictions of biomarker profiles and survival in Oncology with Stan, Monolix and Nonmem
15/10/18PUW1

22/10/18PUW3Rashmi KulkarniMonitoring oxidative stress enables predictions of personalised glucose
targets in diabetic patients
29/10/18PUW3

5/11/18PUW3James Yates
Modelling nonclinical efficacy data for immune-oncology treatments
12/11/18PUW3FrankVancomycin PKPD in children
19/11/18PUW1JohnPhD introduction - nlme in vaccine development
26/11/18LevinskiSoumyaPhD introduction
3/12/18PUW3JayaNeonatal vancomycin CSF PK
10/12/18PUW3Daren AustinOptimised dose for WHO weight bands
7/1/19PUW3Planning meeting
14/1/19PUW3JoeBSAC Antimicrobial chemotherapy meeting practice
21/1/19PUW3

28/1/19PUW3MaddlieClonidine/fentanil PK update
4/2/19PUW1journal club
11/2/19PUW1FrankPredicting clinical outcome in TB
18/2/19PUW1CharlotteNAPPA overview
25/2/19PUW3
Phil Tresadern
popypkpd introduction
4/3/19PUW3SilkePhD work summary
11/3/19PUW3FerranPK paper picking with ML
18/3/19PUW3MaddliePKPD of sedation in neonates
25/3/19PUW3JudePhD Introduction
1/4/19PUW1SoumyaRituximab PD in BMT
8/4/19LEWINSKYZoePhD Introduction
15/4/19PUW3no meetingECCMID
13/5/19PUW3Claire Deakin
Modelling long-term outcomes and estimating treatment efficacy in a rare rheumatic disease
20/5/19PUW3HaifaCaspofungin PK in ECMO
3/6/19PUW1

10/6/19LEVINSKYno meeting
17/6/19PUW3AllPAGE review
24/6/19PUW3CintiaPaediatric Clinical Pharmacology in Buenas Aires
1/7/19PUW3Wen YaoPKPd in Malaysia
8/7/19PUW3JoeTreo PKPD
15/7/19PUW3MaddlieUpgrade practice

Date

Location*

Presenter

Topic

2/9/19LGSRFerranQSP machine learning practice
12/9/19 [NOTE Thurs)PUW2Palang Chotsiri and Richard HoglundMalaria PKPD
16/9/19LGSRPlanning meeting
23/9/19LGSRSimonPeptide PKPD
30/9/19LGSR

7/10/19LGSR

14/10/19LGSRJuliePharmacogenomics and nlme - some applications
21/10/19LGSRFrankTB PKPD
28/10/19LGSRSoumyaB cell reconstitution post HSCT and rituximab
4/11/19LGSRFerranPK parameter extraction with NLP
11/11/19LGSRZoeFosfomycin PK in neonates
18/11/19PUW2JoeMRC interview practice
25/11/19PUW1MaddlieClonidine PKPD in PICU
2/12/19PUW2

9/12/19PUW2SilkeAntimicrobial PKPD
16/12/19PUW2ZahraAntimicrobial in vitro PKPD
  • No labels